OssDsign launches Cranial PSI in Japan and records first sales
Uppsala, June 21, 2022. OssDsign AB (publ.) today announces that the company has completed its first sales of OssDsign Cranial PSI in Japan. The launch marks an important strategic milestone, following a period of postponed commercial activities due to the Covid-19 pandemic.
OssDsign Cranial PSI is a patient-specific cranial implant made from 3D printed medical-grade titanium covered by a regenerative calcium phosphate composition. While the titanium skeleton reinforces the implant and resists physical and mechanical stress, the unique calcium phosphate composition provides healing and regenerative properties, allowing regrowth of the patient's own bone. Over time, the calcium phosphate composition degrades and is replaced with bone, leaving the patient with a well-integrated implant, potentially lasting a lifetime.
“Japan constitutes an important strategic market to our implant technology. Whilst we foresee a gradual ramp-up in the market over the coming quarters and years, I am pleased that our continued perseverance during the pandemic has resulted in the first sales and a formal launch. We will now accelerate our commercial efforts towards more Japanese hospitals,” says Morten Henneveld, CEO of OssDsign.
The total addressable global market for OssDsign’s cranial implants is estimated to USD 400 million, with a CAGR of approximately 7% during 2021–2025. The product is commercially available in more than ten markets worldwide through OssDsign’s direct sales force as well as distributors and independent sales agents.
The most recent clinical data from long-term follow-up of the OssDsign Cranial PSI, based on 1,480 implants across 214 hospitals worldwide, showed that the frequency of infections leading to implant removal was 1.6% after a median follow-up time of 22 months. This positive outcome exceeded what has been observed in previous follow-ups, highlighting the exceptional performance of OssDsign Cranial PSI.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Tags: